药物研究
Search documents
康龙化成背债60亿仍强推13.46亿现金收购 前9月增收不增利关联方套现5亿
Chang Jiang Shang Bao· 2025-11-25 00:06
Core Viewpoint - The acquisition plan by Kanglong Chemical (康龙化成) to purchase 82.54% of Wuxi Baiaode Biological Science Co., Ltd. for approximately 1.346 billion yuan has raised market skepticism due to financial pressures and high premium valuation [1][3]. Group 1: Acquisition Details - Kanglong Chemical plans to acquire 82.54% of Baiaode for 1.346 billion yuan, aiming to enhance its "full-process, integrated, international, and multi-therapy" strategy [1][3]. - The acquisition price reflects a significant premium, valuing Baiaode at approximately 1.631 billion yuan, which is a 168.21% increase over its net assets [3]. - The valuation of Baiaode at 1.5 billion yuan was deemed reasonable by Kanglong, supported by previous market financing rounds [3]. Group 2: Financial Performance - As of September 2025, Kanglong Chemical reported total liabilities of approximately 6 billion yuan and financial expenses of 153 million yuan for the first three quarters of 2025 [2][7]. - The company achieved a record revenue of 10.086 billion yuan in the first three quarters of 2025, but its net profit decreased by 19.76% year-on-year [2][11]. Group 3: Market Reactions and Concerns - The acquisition has raised concerns about related party transactions, as approximately 500 million yuan will be cashed out by related parties through this deal [2][8]. - Kanglong's stock price has significantly declined, dropping over 70% from its peak in August 2021, closing at 29 yuan per share on November 24, 2025 [2][11]. - There has been a notable trend of major shareholders reducing their stakes, with significant cash-outs totaling around 12 billion yuan since 2022 [10][11].
康龙化成发生两人死亡安全事故未信披 公司称未达信披标准
Zhong Guo Jing Ying Bao· 2025-09-22 10:37
Core Viewpoint - The report reveals a fatal accident at Kanglong Chemical (康龙化成), where two employees died due to asphyxiation caused by nitrogen gas in a flexible isolator during a night shift on June 3, 2023. The company failed to disclose this incident in a timely manner, citing it did not meet disclosure standards [4][5][6]. Group 1: Accident Details - The accident occurred in the purification room of Kanglong Chemical's facility in Beijing Economic-Technological Development Area [4]. - The two deceased employees had 6 and 8 years of experience, respectively, and were performing routine tasks when the incident happened [4][5]. - The direct cause of death was identified as a significant drop in oxygen levels due to nitrogen gas being introduced into the flexible isolator without proper safety measures [5][6]. Group 2: Investigation Findings - The investigation concluded that the accident was a result of non-compliance with safety protocols, specifically the failure to use gloves while operating within the flexible isolator [6]. - Indirect causes included inadequate enforcement of safety regulations and insufficient safety training for the employees involved [6]. - The investigation team recommended penalties for 10 management personnel at Kanglong Chemical, including fines based on their annual salaries [6]. Group 3: Company Performance - In the first half of 2025, Kanglong Chemical reported revenue of 6.441 billion yuan, a year-on-year increase of 14.93% [7]. - The net profit attributable to shareholders decreased by 37% to 701 million yuan, while the net profit excluding non-recurring items increased by 36.66% to 637 million yuan [7].